Campiglio M - Search Results

1

Biologic and therapeutic role of HER2 in cancer.

Ménard S, Pupa SM, Campiglio M, Tagliabue E. Ménard S, et al. Among authors: campiglio m. Oncogene. 2003 Sep 29;22(42):6570-8. doi: 10.1038/sj.onc.1206779. Oncogene. 2003. PMID: 14528282 Review.

2

HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N. Ménard S, et al. Among authors: campiglio m. Clin Cancer Res. 2002 Feb;8(2):520-5. Clin Cancer Res. 2002. PMID: 11839672

3

Role of proliferation in HER2 status predicted response to doxorubicin.

Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P, Ménard S. Campiglio M, et al. Int J Cancer. 2003 Jul 1;105(4):568-73. doi: 10.1002/ijc.11113. Int J Cancer. 2003. PMID: 12712452 Free article. Clinical Trial.

4

Role of HER2 in wound-induced breast carcinoma proliferation.

Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Ménard S. Tagliabue E, et al. Among authors: campiglio m. Lancet. 2003 Aug 16;362(9383):527-33. doi: 10.1016/S0140-6736(03)14112-8. Lancet. 2003. PMID: 12932384

5

Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.

Bianchi F, Tagliabue E, Ménard S, Campiglio M. Bianchi F, et al. Among authors: campiglio m. Cell Cycle. 2007 Mar 15;6(6):643-6. doi: 10.4161/cc.6.6.4033. Epub 2007 Mar 20. Cell Cycle. 2007. PMID: 17374991 Free article. Review.

6

HER2 as a target for breast cancer therapy.

Tagliabue E, Balsari A, Campiglio M, Pupa SM. Tagliabue E, et al. Among authors: campiglio m. Expert Opin Biol Ther. 2010 May;10(5):711-24. doi: 10.1517/14712591003689972. Expert Opin Biol Ther. 2010. PMID: 20214497 Review.

7

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.

Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM. Ghedini GC, et al. Among authors: campiglio m. J Cell Physiol. 2010 Oct;225(1):256-65. doi: 10.1002/jcp.22257. J Cell Physiol. 2010. PMID: 20506359

8

Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.

Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM. Ciravolo V, et al. Among authors: campiglio m. J Cell Physiol. 2012 Feb;227(2):658-67. doi: 10.1002/jcp.22773. J Cell Physiol. 2012. PMID: 21465472

9

Activity and resistance of trastuzumab according to different clinical settings.

Tagliabue E, Campiglio M, Pupa SM, Ménard S, Balsari A. Tagliabue E, et al. Among authors: campiglio m. Cancer Treat Rev. 2012 May;38(3):212-7. doi: 10.1016/j.ctrv.2011.06.002. Epub 2011 Jul 2. Cancer Treat Rev. 2012. PMID: 21726959 Review.

10

The HER2 World: Better Treatment Selection for Better Outcome.

Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Tagliabue E, et al. Among authors: campiglio m. J Natl Cancer Inst Monogr. 2011;2011(43):82-5. doi: 10.1093/jncimonographs/lgr041. J Natl Cancer Inst Monogr. 2011. PMID: 22043048

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page